American Medical AssociationLooking for the Optimal Endocrine Partner for ER+, HR+, ERBB2- Advanced Breast Cancer

A phase 2 clinical trial involving 486 patients examined whether fulvestrant or letrozole is more effective in treating advanced breast cancer. The results, published in JAMA Oncology, confirmed that letrozole is the preferred treatment in patients with advanced forms of breast cancer. Although fulvestrant demonstrated significant antitumor activity, it did not significantly impact the overall […]

American Medical AssociationIntervention Reduces “Death Rattle” in End-of-Life Care

Publication: JAMADesign: Multicenter, randomized, double-blind, placebo-controlled trial performed in six hospices in the Netherlands of 162 patients with a life expectancy of three or more days. Administration of subcutaneous scopolamine butylbromide, 20 mg four times a day (n = 79) or placebo (n=78) in the 157 patients included in the primary analysis.Results: A death rattle occurred in […]

Wyanoke GroupProfound Changes in Lipid-Lowering Therapy Coming with New Agents Targeting LP(a) and Triglycerides

Our understanding of lipid pathology is shifting from what might be called the “LDL hypothesis” to the “atherogenic lipoprotein hypothesis.” LDL is just a surrogate of the actual process of lipoprotein interaction with the arterial wall. This shift in understanding is driving a host of budding therapies with novel approaches to targeting key atherogenesis players […]

The BMJMenstrual Changes After COVID-19 Vaccination

This BMJ editorial examines whether approaches better equipped to compare rates of menstrual variation in vaccinated versus unvaccinated populations are needed, based on the reports of changes to periods and unexpected vaginal bleeding after vaccination. The US has taken the first step, earmarking $1.67M from the National Institutes of Health to encourage research.